MEAI

Clearmind Medicine CEO Issues Letter to Shareholders

Retrieved on: 
Tuesday, April 9, 2024
Data monitoring committee, Depression, Obesity, Mevalonate pathway, Psychiatry, Dyskinesia, Addiction, Safety, Binge drinking, Data, DSM-IV codes, Research, MEAI, Clinical trial, Johns Hopkins University, Phase, Patent, Therapy, Ministry, FDA, Impulsivity, CTS, IRB, Pharmaceutical industry

Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.

Key Points: 
  • Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.
  • CMND-100, a pioneering MEAI-based (5-methoxy-2-aminoindane) formula, has exhibited encouraging results in pre-clinical studies.
  • Notably, it has shown the ability to disrupt the destructive cycle of binge drinking without inducing hallucinations—a common concern with existing treatments.
  • The journey ahead is filled with potential, and we eagerly anticipate sharing impactful updates with our shareholders."

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Retrieved on: 
Tuesday, March 19, 2024
Alcoholism, CWY, Binge drinking, MEAI, IP, Patent, Therapy, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional patent approval by the China National Intellectual Property Administration.

Key Points: 
  • The divisional patent approval, previously announced, grants Clearmind a broader claim than patent application.
  • This latest patent builds upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.
  • The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space.
  • Clearmind’s MEAI may also be used to treat binge drinking, which can be a deadly addiction for some.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Retrieved on: 
Wednesday, March 13, 2024
Dopamine, NET, Reward, Sheba Medical Center, CWY, Psychiatry, Serotonin, Patient, Research, MEAI, Alcoholism, Clinical trial, DAT, Safety, Norepinephrine, Yale school, Therapy, Ministry, Pharmaceutical industry

The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Key Points: 
  • The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.
  • The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Retrieved on: 
Monday, February 5, 2024
Binge drinking, Therapy, CWY, Alcoholism, MEAI, IP, Patent, Pharmaceutical industry

The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space.

Key Points: 
  • The granting of this latest patent establishes both the company's patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space.
  • "We are proud to receive once again recognition of our innovative treatment for binge behaviors.
  • “In various pre-clinical studies, carried out during the past 2 years, MEAI has demonstrated its ability to regulate binge behaviors, addiction and other mental health disorders.
  • Clearmind’s MEAI may also be used to treat binge drinking, which can be a deadly addiction for some.

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

Retrieved on: 
Thursday, February 1, 2024
Cocaine, Gonda, Research, Therapy, CWY, Bar-Ilan University, Addiction, MEAI, Animal, Crave, BIRAD, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the signing of an exclusive long-term license agreement with BIRAD, a research & development company of Bar-Ilan University, to use the joint patent it has with BIRAD for innovative cocaine treatment.

Key Points: 
  • Millions are affected by cocaine addiction worldwide, and the successful application of MEAI [5-Methoxy-2-aminoindane] could revolutionize treatment protocols and offer new hope to those trapped in the cycle of addiction.
  • The trial was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning.
  • Animals previously conditioned with cocaine, received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg.
  • This research also demonstrated MEAI’s unique ability to treat cocaine addiction and its potential to become, if approved by regulatory agencies, the first dedicated cocaine addiction treatment.

Clearmind Medicine Completed Type A Meeting with the FDA

Retrieved on: 
Wednesday, January 10, 2024
MEAI, CWY, Serotonin, DAT, Reward, NET, IND, Food, Dopamine, FDA, Therapy, Norepinephrine, Pharmaceutical industry

"We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Key Points: 
  • "We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
  • The active ingredient in CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
  • MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b.
  • The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence.

Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Retrieved on: 
Tuesday, December 5, 2023
MEAI, Cocaine, Research, Bar-Ilan University, Gonda, Hope, CWY, Rat, Patent, Central nervous system, Therapy, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced achievement of positive results in addiction treatment for its revolutionary treatment targeting cocaine addiction.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced achievement of positive results in addiction treatment for its revolutionary treatment targeting cocaine addiction.
  • Our unique psychedelic compound has shown remarkable results in pre-clinical trials for cocaine addiction," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
  • "These promising results from our MEAI-based treatment offer a potential paradigm shift in how we approach the complex challenge of cocaine addiction, an addiction for which no dedicated treatment has yet been developed."
  • As Clearmind Medicine continues to pioneer in the field of psychedelic medicine, this development underscores the company's commitment to harnessing the untapped potential of psychedelic compounds in medical treatment.

Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Retrieved on: 
Friday, December 1, 2023
Hebrew University of Jerusalem, Blood, MEAI, Depression, TEL, Mouse, CWY, Combination, Animal, Appetite, Obesity, PEA, Central nervous system, Carbon, Safety, Therapy, Disorder, Pharmaceutical industry

TEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Key Points: 
  • The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups.
  • A notable reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI.
  • "I am encouraged by the positive results from our recent pre-clinical trial, which represent another milestone in our ongoing efforts to develop safe and effective innovative therapies.
  • "The trial's findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment's efficacy and safety."

Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Retrieved on: 
Friday, December 1, 2023
Hebrew University of Jerusalem, Blood, MEAI, Motivation, Depression, Weight, Weight loss, Mouse, CWY, Hospital, Animal, DSM-IV codes, Appetite, Obesity, PEA, Carbon, Safety, Therapy, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, earlier this week.

Key Points: 
  • Results indicated that:
    The administered treatment exhibited a remarkable degree of tolerance, leaving the mice' viability unaffected across all experimental groups.
  • "We are excited by these latest results of our combination treatment for obesity and metabolic disorders.
  • "Clearmind's treatment targets fat loss while maintaining and elevating energy levels, motivation and other positive influences.
  • "These results from the pre-clinical trial highlight the promising potential of Clearmind's MEAI and SciSparc's PEA combination treatment for obesity and metabolic disorders.